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Abstract
The majority of systemic sclerosis (SSc) patients have gastrointestinal tract involvement, but therapies of prokinetic
agents are usually unsatisfactory. Patients are often compromised by the use of steroid; therefore, a surgical
indication including fundoplication has been controversial. There is no report that advanced SSc with severe
gastroesophageal reflux disease (GERD) is successfully treated with acotiamide, which is the acetylcholinesterase
(AChE) inhibitor designed for functional dyspepsia (FD). We report a 44-year-old woman of SSc with severe GERD
successfully treated with acotiamide. She had received medical treatment in our hospital since 2003. She had been
aware of the significant gastroesophageal reflux symptoms (e.g., heartburn, chest pain, and dysphagia) due to the
development of esophageal hardening associated with SSc since 2014. As a result of upper gastrointestinal series,
upper gastrointestinal endoscopy, and 24-h pH monitoring and frequency scale for the symptoms of the GERD
(FSSG) scoring, she has been diagnosed with GERD associated with SSc. First of all, she started to take prokinetic
agents Rikkunshito and mosapride and proton pump inhibitor; there was no change in reflux symptoms. So, we
started to prescribe her the acotiamide.
After oral administration started, reflux symptoms have been improved. Five months after oral administration, FSSG
score, a questionnaire for evaluation of the symptoms of GERD, was improved. Since its introduction of acotiamide,
the patient has kept free from symptoms for 6 months.
Keywords: acotiamide, systemic sclerosis, gastroesophageal reflux disease (GERD), functional dyspepsia (FD),
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Background
Systemic sclerosis (SSc) is a multisystem and chronic
disease characterized by abnormalities of small blood
vessels and fibrosis of the skin and internal organs.
SSc, when advanced, is often compromised with severe
gastroesophageal reflux disease (GERD), which may be
lethal in a worst-case scenario. A wide variety of medica-
tion has been used [1–5]; however, none of them are
promising for patients with SSc. In addition, patients with
SSc are often compromised by the use of steroid; there-
fore, a surgical indication including fundoplication has
been controversial.
In this short communication, we describe our recent
case of advanced SSc patients with severe GERD, who
was successfully treated with a new drug originally de-
signed for functional dyspepsia (FD).
Case presentation
A 44-year-old woman of SSc had received medical treat-
ment in our hospital since 2003. She had been aware of
the significant gastroesophageal reflux symptoms and
esophagus stasis due to the development of esophageal
hardening associated with SSc since 2014. On physical
examination, cachexia, a “mouse face” appearance and
ulceration in the distal phalanges were identified. The
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abnormal build-up of fibrous tissue in the skin can cause
the skin to tighten so severely that her fingers curl and
lose their mobility (Fig. 1). Because she had been aware
of the worsening of gastroesophageal reflux symptoms,
she received a medical examination from this depart-
ment. Upper gastrointestinal series revealed no expan-
sion and meandering esophagus, and reflux into the
esophagus in the Trendelenburg position (Fig. 2). The
upper gastrointestinal endoscopy showed reflux esopha-
gitis of Los Angeles classification grade C and esophagus
residue (Fig. 3).
A 24-h esophageal pH monitoring revealed significant
acid reflux: the number of refluxes was 81 times, pH
was below 4.0 for 32.1 %, mean pH was 4.55, and
DeMeester score (normal <14.75) was 117.5 (Fig. 4).
Symptoms of gastroesophageal reflux disease (frequency
scale for the symptoms of the GERD (FSSG)) score, a
questionnaire evaluating the symptoms of GERD, was 34
points [6] (maximum 48 points). As a result of these
tests, she has been diagnosed with GERD associated with
SSc. Treatment with Rikkunshito and mosapride, which
are prokinetic agents, and proton pump inhibitor was
started. However, her symptoms were not improved.
Therefore, we started the acotiamide on June 2015,
which was a new drug originally designed for FD. Since
then, her symptoms which were heartburn, burp, and
nausea after a meal were improved. Five months after
acotiamide was started, the FSSG score was reduced to
21 points (Fig. 5). However, the results of 24-h esopha-
geal pH monitoring showed worsening acid reflux: the
number of refluxes was 152 times, pH was below 4.0 for
60.5 %, mean pH was 3.73, and DeMeester score (nor-
mal <14.75) was 211.6 (Fig. 4). The upper gastrointes-
tinal series and upper gastrointestinal endoscopy did not
change.
Since the introduction of acotiamide, the patient has
been free from symptoms to date.
Discussion
In 1994, Sjogren proposed a progression of SSc with
gastrointestinal involvement, vascular damage, neuro-
genic impairment, and myogenic dysfunction with the
replacement of normal smooth muscle by collagens
fibrosis and atrophy [7]. It is distinguished in diffuse
cutaneous SSc (dcSSc) or limited cutaneous SSc (lcSSc)
whether skin hardening exceeds an elbow or a knee [8].
Next to the skin, the gastrointestinal tract is the second
most common site of SSc organ damage that can affect
patients with lcSSc and dcSSc [9]. It affects the gastro-
intestinal tract in more than 80 % of patients. Reflux
esophagitis is found in 50–90 % of SSc patients [7, 10].
The common characteristics of GERD seen in SSc
patients are as follows. The upper GI series often shows
peristaltic decrease and expansion of the lower esophagus.
The upper gastrointestinal endoscopy shows linear
redness and erosion of the lower esophagus caused by the
reflux, which often merges with the Barett esophagus. In
addition, the merger frequency of esophageal cancer is
often in SSc. Esophageal dysmotility leads to impaired acid
clearance, and 24-h monitoring shows prolongation of
esophageal exposure time to gastric acid [11].
Its treatment, either medical or surgical, has been still
challenging. The major medical treatment option includes
Fig. 1 The abnormal build-up of fibrous tissue in the skin can cause
the skin to tighten so severely that fingers curl and lose their
mobility in SSc
Fig. 2 Upper gastrointestinal series revealed no expansion and
meandering esophagus and reflux into the esophagus in the
Trendelenburg position
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use of histamine-2 receptor antagonist (H2RA) and/or
proton pomp inhibitor (PPI) for the purpose of controlling
stimulation and inflammation of the esophageal mucosa
by the gastric acid reflux [12–14]. Surgery, e.g., Nissen
fundoplication, can be considered for drug-resistant reflux
disease [15]. These medical/surgical treatments have
been shown not as promising as those for reflux patients
without SSc [16].
The last option for SSc patients with severe GERD is a
group of prokinetic drugs. A wide variety of prokinetic
agents have been used, such as mosapride citrate, meto-
clopramide, domperidone, erythromycin, octreotide, and
dinoprost [1–5]. However, therapies of traditional proki-
netic agents are usually unsatisfactory for severe GERD
patients.
Acotiamide is the novel prokinetic agent basically de-
signed for FD; it is the acetylcholinesterase (AChE) inhibi-
tor. FD is a chronic disorder of sensation and movement
(peristalsis) in the upper gastrointestinal tract. The acetyl-
choline (Ach) is released from cholinergic nerve terminals
and lets the gastrointestinal tract shrink by binding to the
muscarinic receptor of the gastrointestinal smooth
muscle. It is thought that the Ach is broken down imme-
diately by AChE and enterokinesis is regulated by this re-
action. Acotiamide inhibits AChE and regulates the
resolution of Ach. As a result, it increases the quantity of
ACh available in the synaptic cleft and therefore improves
enterokinesis [17].
We have prescribed a variety of traditional prokinetic
agents, without obtaining even temporary relief of her
symptoms. Therefore, we prescribed acotiamide. We
performed upper gastrointestinal series, gastrointestinal
endoscopy, 24-h pH monitoring, and the quality of life
(QOL) scores for the assessment of gastroesophageal re-
flux before and after oral administration of acotiamide
on this patient. No changes were observed before and
after treatment in the upper GI series and upper gastro-
intestinal endoscopy. Acotiamide does not show the emis-
sion promoting effect on the normal gastric emptying in
rats. However, prior research reports that acotiamide does







































Fig. 4 A 24-h pH monitoring was performed before and after acotiamide oral administration. These four items showed worsening before and
after the administration
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improve the gastric emptying during restraint stress.
Acotiamide might have led to symptom improvement
due to the suppressed response to stress by decreasing the
expression of NmU, a stress-related gene in the hypo-
thalamus, via the vagus nerve [18].We think this may
be a partial reason why our patient showed improvement
of her GI symptoms.
In the 24-h pH monitoring, DeMeester score even
showed a worsening from 117 to 211. However, FSSG,
which is one of the established QOL scoring system,
showed improvement from total 34 to 21 points. FSSG
is a questionnaire composed of 12 questions and classi-
fied into two groups, which are five items related to
“dysmotility” symptoms and seven items to “acid reflux”
symptoms. In our case, the score related to both symp-
toms were improved from 17 to 10 points and 17 points
to 11 points, respectively. As we describe later, these
improvements can be explained by the pharmacological
effects of acotiamide on both the gastric and the esopha-
geal functions.
In fact, this patient was clearly aware of the improve-
ment of clinical symptoms, and QOL has been improved.
In our case, traditional prokinetic agents attempted
prior to acotiamide were not effective. Only acotiamide
showed substantial relief of the patient’s symptom. We
speculated this might be because of these two factors:
(1) pharmacologically, acotiamide may not only affect
the gastric emptying but also improve fundic accommo-
dation of adaptive relaxation, and (2) acotiamide may
directly act on the esophageal body and improve esopha-
geal peristalsis. The authors have reached the above
speculation based on the results of FSSG score: improve-
ments of early satiety and chest discomfort. The question
score “Do you feel full while eating meals?” was improved
from 4 points to 2 points and “Do some things get stuck
when you swallow?” was improved from 3 points to 2
points, respectively.
We just experienced one case; therefore, further accu-
mulation of similar cases is definitely required. In our
case, no objective improvement was observed on clas-
sical 24-h pH monitoring. The authors believe this
examination might not be appropriate as an evaluation
tool of GERD in patients with severe esophageal motor
dysfunction like advanced SSc patients. Novais et al. re-
ported that the 24-h abnormal pH tracings were classi-
fied into three types: (i) 24-h abnormal pH, with a true
GERD pattern, i.e., sharp sudden pH drops, reaching
values below 3 and then returning to usual esophageal
pH (pH 6–7) (Fig. 6a); (ii) 24-h abnormal pH with a pat-
tern suggesting esophageal fermentation due to retained
food, i.e., steady drop of pH not reaching values below
3.0 (Fig. 6b); and (iii) negative 24-h pH, i.e., presence of
physiological reflux (reflux episodes occurring in less
than 4.5 % of total examining time) or zero reflux
(absence of any episode of pH lower than 4.0) [19].
In a 24-h pH monitoring after acotiamide was started,
there were many frequent waveforms of (ii) than
those of (i). The esophageal food fermentation may have
affected the results of this case. The QOL score, including
FSSG is likely to accurately reflect the symptoms of
patients than 24-h pH monitoring. Future tasks are to per-
form a detailed study by using a new method of measuring
such as high resolution manometry.
Conclusions
We have experienced a case of advanced SSc with severe
GERD successfully treated with acotiamide. Acotiamide
might become a help of advanced SSc with severe GERD
patient whose surgical indication has been controversial.
Consent
Written informed consent was obtained from the patient


















Fig. 5 After oral administration of acotiamide, FSSG score was





Fig. 6 A 24-h pH tracing of this patient. True gastroesophageal
reflux (a) and fermentation (b)
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images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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